HRP20260016T1 - Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba - Google Patents

Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba

Info

Publication number
HRP20260016T1
HRP20260016T1 HRP20260016TT HRP20260016T HRP20260016T1 HR P20260016 T1 HRP20260016 T1 HR P20260016T1 HR P20260016T T HRP20260016T T HR P20260016TT HR P20260016 T HRP20260016 T HR P20260016T HR P20260016 T1 HRP20260016 T1 HR P20260016T1
Authority
HR
Croatia
Prior art keywords
relaxin
chain
therapeutic use
lipidated peptides
modified
Prior art date
Application number
HRP20260016TT
Other languages
English (en)
Croatian (hr)
Inventor
Olivier Duclos
Stéphane ILLIANO
Sergio Mallart
Claire MINOLETTI-HOCHEPIED
Elisabetta Bianchi
Raffaele Ingenito
Paola MAGOTTI
Alessia Santoprete
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20260016T1 publication Critical patent/HRP20260016T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20260016TT 2018-01-31 2019-01-30 Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba HRP20260016T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use
EP19702593.5A EP3746467B1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
HRP20260016T1 true HRP20260016T1 (hr) 2026-02-27

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20260016TT HRP20260016T1 (hr) 2018-01-31 2019-01-30 Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba

Country Status (29)

Country Link
US (3) US10961295B2 (https=)
EP (1) EP3746467B1 (https=)
JP (1) JP7295871B2 (https=)
KR (1) KR102755938B1 (https=)
CN (1) CN111770934B (https=)
AR (1) AR114325A1 (https=)
AU (1) AU2019214358B2 (https=)
BR (1) BR112020014834A2 (https=)
CA (1) CA3089657A1 (https=)
CO (1) CO2020008308A2 (https=)
DK (1) DK3746467T3 (https=)
ES (1) ES3058633T3 (https=)
FI (1) FI3746467T3 (https=)
HR (1) HRP20260016T1 (https=)
IL (2) IL316406A (https=)
LT (1) LT3746467T (https=)
MA (1) MA52994A (https=)
MX (1) MX2020008096A (https=)
MY (1) MY199821A (https=)
NZ (1) NZ766762A (https=)
PH (1) PH12020551118A1 (https=)
PL (1) PL3746467T3 (https=)
PT (1) PT3746467T (https=)
RS (1) RS67606B1 (https=)
SG (1) SG11202006903WA (https=)
SI (1) SI3746467T1 (https=)
TW (1) TWI763972B (https=)
UY (1) UY38069A (https=)
WO (1) WO2019149782A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
EP2726502A1 (en) * 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−2を調製する方法
US20160152679A1 (en) 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
EP3838285A1 (en) * 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US20240400638A1 (en) * 2021-08-23 2024-12-05 Guido MAGNI Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
IL276170B1 (en) 2024-11-01
WO2019149782A1 (en) 2019-08-08
KR102755938B1 (ko) 2025-01-20
UY38069A (es) 2019-08-30
IL316406A (en) 2024-12-01
JP7295871B2 (ja) 2023-06-21
ES3058633T3 (en) 2026-03-12
BR112020014834A2 (pt) 2020-12-08
US20190233494A1 (en) 2019-08-01
CN111770934B (zh) 2024-10-18
TW201940505A (zh) 2019-10-16
KR20200116085A (ko) 2020-10-08
US10961295B2 (en) 2021-03-30
IL276170B2 (en) 2025-03-01
TWI763972B (zh) 2022-05-11
DK3746467T3 (da) 2026-01-12
SI3746467T1 (sl) 2026-02-27
AU2019214358B2 (en) 2023-05-25
PT3746467T (pt) 2026-01-13
RS67606B1 (sr) 2026-01-30
SG11202006903WA (en) 2020-08-28
NZ766762A (en) 2026-03-27
US20210292387A1 (en) 2021-09-23
CN111770934A (zh) 2020-10-13
EP3746467A1 (en) 2020-12-09
CA3089657A1 (en) 2019-08-08
FI3746467T3 (fi) 2026-01-16
RU2020126210A (ru) 2022-02-28
LT3746467T (lt) 2026-01-26
CO2020008308A2 (es) 2020-10-30
PH12020551118A1 (en) 2021-07-05
MY199821A (en) 2023-11-23
PL3746467T3 (pl) 2026-04-13
MA52994A (fr) 2021-05-05
US20240218042A1 (en) 2024-07-04
AU2019214358A1 (en) 2020-08-20
IL276170A (en) 2020-09-30
AR114325A1 (es) 2020-08-19
US11725036B2 (en) 2023-08-15
MX2020008096A (es) 2020-09-24
EP3746467B1 (en) 2025-10-08
JP2021512099A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
HRP20260016T1 (hr) Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
IL279897A (en) Fusosome compositions and uses thereof
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
IL272069A (en) Dosage regimens of anti-lag-3 antibodies and uses thereof
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
EP3709882A4 (en) DIAGNOSTIC AND THERAPEUTIC SPLINTS
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
IL269158A (en) Compositions and methods for treating inflammatory diseases
HUE060791T2 (hu) Antigén peptidek rák megelõzésére és kezelésére
IL281866A (en) Introducer devices and methods of use thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugates
IL269844A (en) Dosing regimens and related compositions and methods
EP3618865A4 (en) HUMAN ANTI-SEMAPHORINE 4D ANTIBODY
KR102735988B9 (ko) 치료 항체 제제
HUE058289T2 (hu) Brómdomén és extraterminális protein inhibitor kombinációs terápia
PL3600415T3 (pl) Przeciwciało przeciwko receptorowi aktywiny typu II do stosowania w leczeniu niewydolności serca
EP3858866A4 (en) GLP1-FC FUSION PROTEIN AND ASSOCIATED CONJUGATE
IL281608A (en) Anti-human cd45rc antibodies and uses thereof
EP3570867A4 (en) THERAPEUTIC PEPTIDES AND NEUROPROTECTORS
EP3476860A4 (en) Recombinant single-chain fviii and chemical conjugate thereof
EP4013440A4 (en) THERAPEUTIC PEPTIDES
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies